Get access

Humanized animal models for autoimmune diseases

Authors

  • J.W. Gregersen,

    1. Department of Clinical Immunology, Aarhus University Hospital, Skejby Sygehus, N Aarhus, Denmark
    Search for more papers by this author
    • These authors contributed equally to this work.

  • S. Holmes,

    1. MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, The University of Oxford, Oxford, UK
    Search for more papers by this author
    • These authors contributed equally to this work.

  • L. Fugger

    Corresponding author
    1. Department of Clinical Immunology, Aarhus University Hospital, Skejby Sygehus, N Aarhus, Denmark
    2. MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, The University of Oxford, Oxford, UK
    Search for more papers by this author

Lars Fugger
MRC Human Immunology Unit
Weatherall Institute of Molecular Medicine
John Radcliffe Hospital
The University of Oxford
Oxford OX3 9DS, UK
Tel.: 01865 222351
e-mail: lars.fugger@imm.ox.ac.uk

Abstract

Abstract:  The development of transgenic mice expressing human DR and DQ major histocompatibility complex (MHC) class II molecules has been of value in studying the immunopathology of human MHC class II-associated autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, insulin-dependent diabetes mellitus and celiac disease. Such mice have been used to identify the target antigens that are involved in the initiation of these diseases. Many of the mice develop aspects of the human diseases, either spontaneously or following immunization with the relevant antigen, thus providing an in vivo disease model, which may be used as a tool for further understanding the disease mechanisms and testing novel immunotherapies.

Ancillary